The news is directly about Edgewise Therapeutics. The Outperform rating suggests that the analyst expects the stock to do better than the market average, which is a positive signal. However, the lowering of the price target might indicate a reduced growth expectation, which could have a neutral to slightly negative impact on the stock price in the short term.